Meningiomas represent the most common primary intracranial neoplasms. Often discovered incidentally during imaging for unrelated conditions, these tumors present a significant clinical dilemma: when does a "silent" tumor become a clinical threat? A recent study published in Frontiers in Neurology (originally appearing as a preprint on Research Square) has identified a specific volumetric threshold that predicts the onset of symptoms with high accuracy.
The Clinical Dilemma: Observation vs. Intervention
Because many meningiomas are slow-growing and benign, clinicians often adopt a strategy of "watchful waiting," using periodic MRI scans to monitor growth. However, the timing of surgical intervention is critical. Operating too early on an asymptomatic patient introduces unnecessary surgical risk, while waiting too long can lead to irreversible neurological deficits.
Previous research has suggested that tumor size is a factor, but these studies often grouped various types of meningiomas together. This study focused specifically on convexity, parasagittal, and falx meningiomas. These tumors are located in the upper portion of the skull and typically do not compress cranial nerves; instead, their symptoms—such as motor deficits or epilepsy—are primarily driven by mass effect and pressure on the brain.
Methodology: Beyond 2D Measurements
Researchers at Osaka University conducted a retrospective analysis of 333 patients treated between 1990 and 2020. The cohort was divided into an asymptomatic group (250 cases) and a symptomatic group (83 cases).
To achieve a higher level of precision than standard 2D diameter measurements, the team employed volumetric analysis. Using Horos software, they manually traced tumor boundaries across every MRI slice to calculate the actual 3D volume. Statistical significance was determined through univariate and multivariate logistic regression, while Receiver Operating Characteristic (ROC) curves were used to identify the optimal threshold for symptomatic progression.
The 21.1 ml Threshold
The study’s most significant finding is the identification of 21.1 ml as the critical volume threshold. With an Area Under the Curve (AUC) of 0.919, this metric proved to be an exceptionally strong predictor of clinical symptoms.
Key results from the analysis include:
- Threshold Volume: 21.1 ml (Sensitivity: 0.843, Specificity: 0.880).
- Threshold Diameter: 40 mm (Sensitivity: 0.819, Specificity: 0.840).
- Independent Predictors: Multivariate analysis confirmed that age, peritumoral edema, and tumor volume are the three most critical factors in symptom development.
The researchers noted that while a 40 mm diameter is also a useful indicator, volumetric analysis is superior because it captures the true "mass effect" on brain tissue. Tumors are rarely perfectly spherical, and volume provides a more accurate representation of the space occupied within the cranium.
The Role of Peritumoral Edema
Another vital "red flag" identified was peritumoral edema—swelling in the brain tissue surrounding the tumor. With an odds ratio of 5.94, the presence of edema was a massive predictor of symptoms. This suggests that once a tumor begins to cause surrounding inflammation, clinical symptoms are likely imminent, regardless of the tumor's absolute size.
Conclusion and Future Directions
This research provides neurosurgeons with a data-driven "line in the sand" for managing incidental meningiomas. By identifying the 21.1 ml threshold, clinicians can move away from subjective observation toward a more objective, predictive model of patient care.
While the study is limited by its retrospective nature and single-center data, it sets the stage for future work. Automated, AI-driven volumetric segmentation and prospective trials could further refine these thresholds, potentially allowing for preventative interventions that stop neurological deficits before they ever begin.
Summary updated